Expanding our knowledge of dry AMD

Article

Professor Scott Cousins explains how we can use our knowledge of drusen formation to find new ways to combat dry age-related macular degeneration.

Key Points

Drusen development: the four theories

Currently, there are four key theories for explaining drusen formation. These are:

The role of inflammation

Our understanding of the disease has evolved rapidly in recent years. "I think that the greatest breakthrough in understanding the pathogenesis of drusen that we have had in the last five to seven years is this idea that inflammation, in various forms, is a major contributor to the disease; that the innate immune system plays a major role," asserted Professor Cousins. "In the last three years, there has been a lot of data published that show that the genetic impetus of AMD is found among the complement inhibitors in the complement system; specifically, Complement Factor H is the most important susceptibility gene.

"My laboratory, among others, has also looked at the role of one of the circulating white cells: the monocyte. We already know that its tissue equivalent, the macrophage, has a major role to play in wet AMD, but we're now learning it plays a role in dry AMD as well, and so we're exploring what this may mean for the development of the disease," Professor Cousins explained.

"The most recent breakthrough in our understanding was published in a New England Journal of Medicine article,"1 Professor Cousins continued. As previously reported by Ophthalmology Times Europe,2 this study examined the role of a mutation of the toll-like receptor 3 (TLR3) gene. TLR3 is a protein that alerts the immune system to infections, and a mutated form of the TLR3 gene, expressing leucine instead of phenylalanine, was shown to be protective against geographic atrophy, most likely by suppressing the death of RPE cells.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.